TG Therapeutics, Inc. (TGTX)
NASDAQ · Manufacturing · Pharmaceutical preparations
$57.40−$0.1200 (−0.21%) on the dayAs of the close; data may be delayed.
TGTX price, last 12 months
Key stats
- Previous close
- $57.52
- Open
- $57.80
- Day range
- $56.61 – $58.69
- 52-week range
- $26.76 – $59.30
- Volume
- 806.7K
- Avg volume (20 days)
- 1.8M
- Market cap
- $8.8B
Performance
1W+0.9%
1M+4.3%
3M+2.8%
6M+79.5%
YTD+92.6%
1Y+62.1%
vs S&P 500, 1Y+45.3 pts
Technicals and fundamentals
About TG Therapeutics, Inc.
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $8.8B